Head-to-head · free

Rhythm Pharmaceuticals, Inc. vs Sol-Gel Technologies Ltd.

RYTM vs SLGL — return on capital, cash generation, margins and balance sheet side by side.

RYTM

1 / 3

measures where RYTM leads

SLGL

2 / 3

measures where SLGL leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureRYTM · FY2025SLGL
Revenue$189.8M—
Net income(196.5M)—
Revenue growth (yearly, multi-year)56.5%—
Free cash flow(116.6M)—
Free cash flow margin-61.5%—
Net cash / (debt)——
ROIC——
Return on equity-251.1%-23.7%
Gross margin89.7%—
Operating margin-101.2%-38.9%
Net debt / EBITDA0.28x1.49x

Figures are as reported by each company; latest fiscal year shown.

Where Rhythm Pharmaceuticals, Inc.'s cash went (FY2025)

Capital spending
$953000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full RYTM profile →

Where Sol-Gel Technologies Ltd.'s cash went

Not reported yet.

Full SLGL profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons